Organophosphates inhibit acetylcholinesterase, leading to an accumulation of acetylcholine at nerve synapses and neuromuscular junctions. This results in continuous stimulation of muscles, glands, and central nervous system structures, causing symptoms like muscle twitching, respiratory distress, and convulsions. Pralidoxime reactivates the inhibited enzyme by cleaving the bond between the organophosphate and the enzyme, thus restoring normal enzyme function.
